Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)
Public ClinicalTrials.gov record NCT04056611. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Study identification
- NCT ID
- NCT04056611
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Interventions
- JNJ-53718678 250 mg Drug
- Placebo Drug
- JNJ-53718678 125 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 13 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 25, 2019
- Primary completion
- Feb 3, 2022
- Completion
- Feb 3, 2022
- Last update posted
- Feb 3, 2025
2019 – 2022
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| Henry Ford Hospital - Hematology/oncology | Detroit | Michigan | 48202 | — |
| University Of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Northwell Health Cancer Institute | Lake Success | New York | 11042 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Baylor Scott and White Research Institute | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center - University of Texas | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04056611, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04056611 live on ClinicalTrials.gov.